 DiaMedica Therapeutics Inc. Nasdaq: DMAC, a clinical-stage biotechnology company, today announced that the Company will be presenting a poster titled Open-label Study of the Pharmacokinetics, Safety, and Tolerability of DM199 in Patients with Diabetes and Chronic Kidney Disease at the National Kidney Foundation NKF 2020 Spring Clinical Meetings Live Virtual Conference. For information about the virtual event, visit: 